Share This Article:

Stability Indicating RP-HPLC Method for the Determination of Dronedarone Hydrochloride and Its Potential Process-Related Impurities in Bulk Drug and Pharmaceutical Dosage Form

Abstract Full-Text HTML Download Download as PDF (Size:1231KB) PP. 323-335
DOI: 10.4236/ajac.2013.46041    4,383 Downloads   6,847 Views   Citations

ABSTRACT

Simple, sensitive and accurate stability indicating analytical method for dronedarone has been developed and validated using RP-HPLC technique. Developed method is used to evaluate the assay and related substances of dronedarone drug substance and tablets (Multaq?). The drug substance was subjected to the stress conditions such as hydrolysis (acid and base), oxidation, photolysis and thermal degradation as per International Conference on Harmonization (ICH) pre- scribed stress conditions to show the stability-indicating the nature of the method. Significant degradation was observed during acid and base hydrolysis, and peroxide degradation. The major degredants were identified by LC-MS, FTIR and 1H NMR spectral analysis. The chromatographic conditions were optimized using an impurity-spiked solution and the samples generated from forced degradation studies. In the developed HPLC method, the resolution between dronedar- one, process-related impurities, (namely Imp-1, Imp-2, Imp-3, Imp-4, Imp-5, Imp-6, Imp-7, Imp-8, Imp-9, Imp-10 and Imp-11) and degradation products were found to be greater than 1.5. The eleven potential process related impurities were separated on an Ascentis? Express C18 column (4.6 × 10 cm i.d., particle size 2.7 μm) at a flow rate of 1.2 mL.min-1. The LC method employed a linear gradient elution and the detection wavelength at 220 nm. The chroma- tographic behavior of all the impurities was examined under variable compositions of different solvents, temperatures and pH values.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

S. Landge, S. Jadhav, K. Nimbalkara, A. Mali and V. Mathad, "Stability Indicating RP-HPLC Method for the Determination of Dronedarone Hydrochloride and Its Potential Process-Related Impurities in Bulk Drug and Pharmaceutical Dosage Form," American Journal of Analytical Chemistry, Vol. 4 No. 6, 2013, pp. 323-335. doi: 10.4236/ajac.2013.46041.

References

[1] “Australian Public Assessment Report for Dronedarone Hydrochloride,” Submission No: PM-2008-3045-3, 2010. http://www.tga.gov.au/pdf/auspar/auspar-multaq.pdf
[2] Assessment Report for Multaq, “Evaluation of Medicines for Human Use,” European Medicines Agency, Procedure No. EMEA/H/C/001043, 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/001043/WC500044538.pdf
[3] Center for Drug Evaluation and Research, “Chemistry Review(s),” Application Number: 22-425, 2009. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ChemR.pdf
[4] FDA, “FDA Approves Multaq to Treat Heart Rhythm Disorder,” 2009.
[5] S. B. Bari, B. R. Kadam, Y. S. Jaiswal and A. A. Shirkhedkar, “Impurity Profile: Significance in Active Pharmaceutical Ingredient,” Eurasian Journal of Analytical Chemistry, Vol. 2, No. 1, 2007, pp. 177-189.
[6] S. Gorog, “The Importance and the Challenges of Impurity Profiling in Modern Pharmaceutical Analysis,” Trends in Analytical Chemistry, Vol. 25, No. 8, 2006. doi:10.1016/j.trac.2006.05.011
[7] C. Xie, S. L. Yang, D. F. Zhong, X. J. Dai and X. Y. Chen, “Simultaneous Determination of Dronedarone and Its Active Metabolite Debutyldronedarone in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study,” Journal of Chromatography B, Vol. 879, No. 28, 2011, pp. 3071-3075.
[8] D. Patel and A. Choudhury, “Development and Validation of Dronedarone HCl In Plasma by RP-HPLC Method Coupled with UV-Detector,” Inventi Impact: Biomedical Analysis, Vol. 2012, 2012, Article ID: Inventi:pba/47/12. http://www.inventi.in/Article/pba/47/12.aspx
[9] N. Tondepu1, S. S. Sait, K. V. Surendranath, R. K. Kaja1 and S. Kumar, “A Stability Indicating HPLC Method for Dronedarone in Bulk Drugs and Pharmaceutical Dosage Forms,” American Journal of Analytical Chemistry, Vol. 3, 2012, pp. 544-551. doi:10.4236/ajac.2012.38072
[10] A. Patel and J. Akhtar, “RP-HPLC Method Development and Validation of Dronedarone HCl in Its Pure Form and Tablet Dosage Form,” Journal of Chemical and Pharmaceutical Research, Vol. 4, No. 4, 2012, pp. 2173-2179.
[11] B. Dabhi, Y. Jadeja, M. Patel, H. Jebaliya, D. Karia and A. Shah, “Method Development and Validation of Stability- Indicating RP-HPLC Method for Quantitative Analysis of Dronedarone Hydrochloride in Pharmaceutical Tablets,” Scientific Pharmacology, in press, pp. 1209-1215.
[12] US Food and Drug Administration, “ICH Guidelines on Impurities in New Drug Substances Q3A(R2),” Federal Register, FDA, Silver Spring, 2006.
[13] US Food and Drug Administration, “ICH Guidelines on Impurities in New Drug Substances Q7A,” Federal Register, FDA, Silver Spring, 2005.
[14] A. C. Mali, S. S. Ippar, M. S. Bodke, N. S. Patil and V. T. Mathad, “An Improved, and Efficient Process for the Production of Dronedarone Hydrochloride, an Antiarrhythmic Drug,” Organic Process Research & Development, Vol. 17, No. 5, 2013, pp. 863-868.
[15] The United States Pharmacopeia, “Validation of Compendial Methods,” 2008.
[16] US Food and Drug Administration, “ICH Guidelines on Validation of Analytical Procedures, Text and Methodology Q2(R1),” Federal Register, FDA, Silver Spring, 2005.
[17] J. T. Carstensen and C. T. Rhodes, “Drug Stability Principles and Practices,” 3rd Edition, Marcel Dekker, New York, 2000.

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.